RxDoctor Payments Data

Bryan Huffman, MD

Ophthalmology · Zeeland, MINPI 1013999853

Payments from drug & device makers

$2,064in general payments, 2019–2025

Across 89 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$529
  • Kala Pharmaceuticals, Inc.$218
  • Oyster Point Pharma, Inc.$190
  • AbbVie$181
  • Sun Pharmaceutical Industries Inc.$123
  • Novartis$108
  • plus $716 from 13 others

What the payments were for

  • Food & beverage$2,064100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,064 in reported general payments places this provider in the 60th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$95,405
Medicare patients
341
Services billed
713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$47,947
LumiganBimatoprost16$10,220
Latanoprost437$9,535
Brimonidine Tartrate58$7,673
Cyclosporine15$6,832
Prednisolone Acetate234$6,253
Dorzolamide-TimololDorzolamide/Timolol/Pf16$5,552
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat139$5,234
Bimatoprost20$4,065
Fluorometholone38$2,937
Timolol Maleate113$2,864
Bromfenac Sodium22$2,681
Ketorolac Tromethamine131$1,794
Dorzolamide Hcl30$994
MoxifloxacinMoxifloxacin Hcl38$692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$181$58,16759 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Zeeland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →